Sanofi (NASDAQ:SNY) Shares Sold by Financial Advocates Investment Management

Financial Advocates Investment Management cut its holdings in Sanofi (NASDAQ:SNY) by 9.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,709 shares of the company’s stock after selling 618 shares during the period. Financial Advocates Investment Management’s holdings in Sanofi were worth $275,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of SNY. Charles Schwab Investment Management Inc. boosted its stake in Sanofi by 31.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after acquiring an additional 33,105 shares during the period. Arkadios Wealth Advisors lifted its holdings in shares of Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after purchasing an additional 751 shares during the last quarter. Geode Capital Management LLC boosted its position in Sanofi by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after purchasing an additional 16,780 shares during the period. JPMorgan Chase & Co. grew its stake in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after buying an additional 399,301 shares during the last quarter. Finally, GFS Advisors LLC increased its position in Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after buying an additional 11,655 shares during the period. Institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the subject of several analyst reports. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Sanofi currently has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Trading Up 0.9 %

NASDAQ:SNY opened at $53.35 on Monday. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The business has a fifty day moving average of $49.72 and a 200-day moving average of $52.39. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. The stock has a market cap of $135.39 billion, a price-to-earnings ratio of 21.43, a PEG ratio of 0.99 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. Equities analysts predict that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.